OmniAb, Inc. (OABI) Stock Price & How to Invest

OmniAb was spun out of Ligand Pharmaceuticals in November 2022 and sells access to antibody discovery technology rather than drugs. Its platform centres on transgenic animals engineered to produce human-sequence antibodies (OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniClic) plus the xPloration high-throughput single-cell screening system and an ion channel screening group acquired with Icagen. Partners license the platforms, run their own discovery campaigns, and owe OmniAb payments at defined points: an upfront or annual access fee, service and instrument revenue, clinical and regulatory milestones, and a royalty on eventual product sales. As of Q2 2026 there were ~110 active partners, ~425 active programs, ~34 of those in clinical development or already approved, eight of the ten largest pharma companies among the partner base, and roughly 98% of programs carrying contracted future economics. Management has cited more than ~$3B of total contracted milestone potential at an average royalty near ~3.4%.

The investment picture is unusually lumpy, because the revenue arrives when somebody else's molecule moves. Q2 2026 revenue was ~$13.4M against ~$3.9M a year earlier, almost entirely on license and milestone payments as programs such as Johnson & Johnson's ramantamig and Merck KGaA's precemtabart tocenteban jumped from Phase 1 into Phase 3. Net loss narrowed to ~$5.9M from ~$15.9M, and first-half operating cash burn fell to ~$2.2M from ~$21.0M. Set against that, trailing twelve-month revenue is only ~$38M on a ~$491M market value (roughly ~12.8x sales), the trailing net loss is ~$44M once amortisation of acquired intangibles is counted, and royalty revenue itself was just ~$0.3M in the quarter. On 17 August 2026 the company added a global collaboration and license agreement with Eli Lilly for an ion channel program and lifted year-end cash guidance to ~$49M to ~$53M from ~$37M to ~$41M, while leaving the 2026 revenue range at ~$32M to ~$36M.

Revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. OmniAb controls none of the programs that pay it, so a partner deprioritising a molecule, a failed trial, or a slipped filing removes a milestone with no offsetting action available. The company remains unprofitable on a trailing basis (~$44M net loss) with a large non-cash amortisation charge on acquired intangibles, and Q1 2026 included a ~$2.9M impairment of a customer relationship intangible after ion channel programs were discontinued. Dilution mechanics are real even without an equity raise: ~145.4M shares outstanding sit alongside ~14.99M price-vesting earnout shares, ~18.6M warrants expiring 1 November 2027, and ~$88.3M of unused ATM capacity. Liquidity itself is not flagged as a concern (the 10-Q states cash is sufficient for at least twelve months and no going-concern warning is disclosed, no material pending legal proceedings are reported, and the shares remain listed on Nasdaq with no delisting determination), but the stock has traded between ~$1.30 and ~$3.64 over the past year and rose ~37% on the Q2 print, so the market value moves far more than the underlying contracts do.

6 analysts publish price targets on OABI, averaging $7.33 against a $3.38 price as of August 2026, or +116.9%. The published targets run from $3.00 to $11.00, a wide spread, and the ratings split 7 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full OABI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on OmniAb, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Clinical graduation across ~34 partner programs. The economics compound only as partner molecules move through phases, and 2026 delivered several jumps at once, including two programs advancing from Phase 1 to Phase 3 and four new clinical entrants through mid-year. The most optimistic published target, $11.00, assumes this works close to its best case.

The case against. Revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. The most pessimistic target, $3.00, is roughly what OABI is worth if this bites instead.

Read the full bull and bear case on OABI, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see OmniAb, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$38M
• Q2 2026 revenue: ~$13.4M, up from ~$3.9M a year earlier
• 2026 revenue guidance: ~$32M to ~$36M
• Net loss: ~$5.9M in Q2 2026, ~$44M trailing twelve months
• Cash and short-term investments: ~$52M at 30 June 2026; year-end guidance raised to ~$49M to ~$53M
• Market value / price to sales: ~$491M, roughly ~12.8x TTM revenue

A ~12.8x multiple on ~$38M of trailing revenue is a platform multiple, not a biotech-pipeline multiple, and it reflects contracted future economics rather than current profit. Two figures pull against each other: the milestone line tripled year over year while the royalty line was ~$0.3M for the quarter, so the near-term earnings power comes from stage payments rather than product sales. Cash of ~$52M with essentially no debt and first-half operating burn of ~$2.2M means the balance sheet is not the pressing question at these levels; the timing of partner programs is.

Other names that sit close to OABI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get OABI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so OABI sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where OABI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

OABI is an indirect bet on other companies' clinical timetables, where Q2 2026 finally showed the milestone economics working and the loss shrinking, but the royalty line is still measured in hundreds of thousands of dollars.

Whether OABI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OABI a buy or a sell?, and where the stock could go from here in the OABI stock forecast.

For income investors, whether OABI pays a dividend and how the payout looks is covered in does OABI pay a dividend? And to weigh OABI against a peer, read the full side-by-side comparisons: OABI vs REGN and OABI vs HNGE.